Advanced or Metastatic Breast Cancer
Conditions
Keywords
breast cancer, Palbociclib
Brief summary
The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice. This study also looks at the safety of Ibrance, including any side effects. Side effects are undesired effects of a medicine or other type of treatment. This study will include the data of the following participants: * Adult women (more than18 years of age) with at least one visit with a breast cancer * Patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage III, stage IV. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the cancer which is spread from the place where it started to other places in the body. * Patients with a laboratory test positive for hormone receptor and negative for HER2 before or up to 60 days after advanced/metastatic breast cancer diagnosis date. * Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer. This study will look at the safety of palbociclib treatment by looking at the number and severity of the side effects.
Interventions
DRUGIbrance
Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Adult women (≥ 18 years of age) with at least one visit with a breast cancer ICD10 diagnosis code (C50.x) * Patients with locally advanced breast cancer or metastatic breast cancer with a staging classification of stage III, stage IV (distant metastases). * Patients with a laboratory test positive for hormone receptor (HR) and negative for human epithelial growth factor receptor 2 (HER2) before or up to 60 days after advanced/metastatic breast cancer diagnosis date. 1. HR-positive is defined as any positive test for estrogen receptor or progesterone receptor. 2. HER2-negative is defined as any HER2-negative test and the absence of a positive test (immunohistochemistry positive (3+), fluorescence in situ hybridization positive/amplified). * Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer
Exclusion criteria
Patients meeting any of the following criteria will not be included in the study: * Breast cancer with HR-negative and HER2-positive on laboratory testing. * More than a 90-day gap between breast cancer diagnosis date and next visit. * Patients who treated as off-label
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events that occur during treatment | From index date to last dose plus 28 days. Index is defined as the date of first prescription of Ibrance on participants diagnosed between 29 Aug 2015 through 30 Sep 2023 |
| Number of participants with associated risk factors | From index date to last dose plus 28 days. Index is defined as the date of first prescription of Ibrance on participants diagnosed between 29 Aug 2015 through 30 Sep 2023 |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | From baseline to the date of death or censoring date, whichever occurs first on participants diagnosed between 29 Aug 2015 through 30 Sep 2023 |
| Real-World Tumor Response (rwTR) | From baseline to the date of death or censoring date, whichever occurs first on participants diagnosed between 29 Aug 2015 through 30 Sep 2023 |
Countries
United States
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed